NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Don't confuse regulatory framing with biological function.

Karin Smyth was responding to a formal parliamentary question about the MHRA’s decision timeline regarding DCVax-L’s licensing. The question itself framed DCVax-L as “the personalised immunotherapy developed to treat the malignant brain tumour glioblastoma.” Her reply echoed that scope of language. It was NOT a denial of DCVax-L's broader potential or mechanism of actions across caner types.

DCVax-L is built on a patient-specific, tumor-targeted mechanism: dendritic cells are extracted from the patient’s blood and “educated” using lysate from that patient’s own tumor tissue. These trained cells are then reintroduced to stimulate a targeted immune response—not against a generic cancer type, but against the unique antigens of that individual’s tumor. That’s why DCVax-L is considered cancer agnostic. It doesn’t rely on markers unique to glioblastoma—or any specific tissue type. It targets tumor-specific antigens derived from each patient’s tumor, regardless of origin.

This isn’t speculative. The NHS validated DCVax-L’s agnostic mechanism by placing it on the High Cost Drug list—not just for glioblastoma, but with recognition of its broader potential.

So say whatever you want. Deny what’s plainly in front of you. But the question is no longer if DCVax-L is agnostic. The question is when will regulatory agencies formally designate it as such—and expand the licensing to reflect what the science and clinical data already show. The NHS has already taken that step. Others will follow, assuming they haven't already.